The Interaction of Botrocetin with Normal or Variant von Willebrand Factor (Types IIA and IIB) and Its Inhibition by Monoclonal Antibodies that Block Receptor Binding
Yoshihiro Fujimura(Japanese Red Cross Society, Japan), Koiti Titani(Gifu Pharmaceutical University), Edward G. D. Tuddenham, Hiromu Fukui(National Archives and Records Administration), Masahiko Katayama(Takara (Japan)), Akira Yoshioka(Kyoto University), Sachiyo Nishida(National Blood Transfusion Service), M. Kaneda(Nara Medical University), Shigeki Miyata(Japanese Red Cross Society, Japan), S Miura(Nara Medical University), Yoshiko Usami(University of Massachusetts Chan Medical School)
Cited by 17
Related Papers
Human Recombinant DNA–Derived Antihemophilic Factor (Factor VIII) in the Treatment of Hemophilia A
|New England Journal of Medicine|1990|266
Structural Basis for Budding by the ESCRT-III Factor CHMP3
|Developmental Cell|2006|254
Genetic mapping and diagnosis of haemophilia A achieved through a BclI polymorphism in the factor VIII gene
|Nature|1985|232
Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface
|Biochemical Journal|1993|213